Microfluidic encapsulated manganese organic frameworks as enzyme mimetics for inflammatory bowel disease treatment

Metal organic frameworks (MOFs) with physicochemical properties and adjustable structures have been proposed as very attractive materials. The studies on development of such functional materials tended to fabricate featured MOF objects with fascinating catalytic capabilities to utilize their biomedical values. In this paper, we present novel biocompatible manganese metal organic framework (Mn-MOF)-based catalase mimetics with microfluidic microcapsule encapsulation for intravital inflammatory bowel disease (IBD) treatment. Phosphoserine, a component of the cell membrane, served as an organic ligand to ensure biocompatibility of Mn-MOF. Owing to the core-shell structure of the microcapsule, the Mn-MOF exhibited a well-organized distribution and controlled release features, which could protect them from gastric juice and provide function in the intestine. Upon reaching the sites of the inflammatory bowel, Mn-MOF could effectively scavenge reactive oxygen species (ROS) over-produced by neutrophils and macrophages under various gastrointestinal pH environments, protecting intestinal epithelial cells from ROS damage. The Mn-MOF-encapsulated microcapsules exhibited high performances in treating spontaneous IBD in interleukin-10-deficient mice by relieving the oxidative stress, reducing the inflammation, and restoring the intestinal barrier. These results indicate that the functional Mn-MOF-encapsulated microcapsules have practical applications in the treatment of ROS-associated diseases. (c) 2021 Elsevier Inc. All rights reserved.

Automated summary

Metal organic frameworks (MOFs) are proposed as attractive materials for their adjustable structures and physicochemical properties, with a focus on developing functional materials with catalytic capabilities for biomedical values. Biocompatible manganese metal organic framework (Mn-MOF)-based catalase mimetics with microfluidic microcapsule encapsulation were presented for intravital inflammatory bowel disease (IBD) treatment. These Mn-MOF-encapsulated microcapsules showed high performance in treating spontaneous IBD in interleukin-10-deficient mice by relieving oxidative stress and reducing inflammation.